title: PET imaging of chemokine receptors in vascular injury-accelerated atherosclerosis.
abstract: Atherosclerosis is the pathophysiologic process behind lethal cardiovascular diseases. It is a chronic inflammatory progression. Chemokines can strongly affect the initiation and progression of atherosclerosis by controlling the trafficking of inflammatory cells in vivo through interaction with their receptors. Some chemokine receptors have been reported to play an important role in plaque development and stability. However, the diagnostic potential of chemokine receptors has not yet been explored. The purpose of this study was to develop a positron emitter-radiolabeled probe to image the upregulation of chemokine receptor in a wire-injury-accelerated apolipoprotein E knockout (ApoE(-/-)) mouse model of atherosclerosis.
  
  
  METHODS
  A viral macrophage inflammatory protein II (vMIP-II) was used to image the upregulation of multiple chemokine receptors through conjugation with DOTA for (64)Cu radiolabeling and PET. Imaging studies were performed at 2 and 4 wk after injury in both wire-injured ApoE(-/-) and wild-type C57BL/6 mice. Competitive PET blocking studies with nonradiolabeled vMIP-II were performed to confirm the imaging specificity. Specific PET blocking with individual chemokine receptor antagonists was also performed to verify the upregulation of a particular chemokine receptor. In contrast, (18)F-FDG PET imaging was performed in both models to evaluate tracer uptake. Immunohistochemistry on the injury and sham tissues was performed to assess the upregulation of chemokine receptors.
  
  
  RESULTS
  (15)O-CO PET showed decreased blood volume in the femoral artery after the injury. (64)Cu-DOTA-vMIP-II exhibited fast in vivo pharmacokinetics with major renal clearance. PET images showed specific accumulation around the injury site, with consistent expression during the study period. Quantitative analysis of tracer uptake at the injury lesion in the ApoE(-/-) model showed a 3-fold increase over the sham-operated site and the sites in the injured wild-type mouse. (18)F-FDG PET showed significantly less tracer accumulation than (64)Cu-DOTA-vMIP-II, with no difference observed between injury and sham sites. PET blocking studies identified chemokine receptor-mediated (64)Cu-DOTA-vMIP-II uptake and verified the presence of 8 chemokine receptors, and this finding was confirmed by immunohistochemistry.
  
  
  CONCLUSIONS
  (64)Cu-DOTA-vMIP-II was proven a sensitive and useful PET imaging probe for the detection of 8 up-regulated chemokine receptors in a model of injury-accelerated atherosclerosis.
authors: Department of Radiology, Washington University, St. Louis, Missouri 63110, USA. liuyo@mir.wustl.edu
authors: Yongjian
authors: Y
authors: Liu
authors: Richard
authors: R
authors: Pierce
authors: Hannah P
authors: HP
authors: Luehmann
authors: Terry L
authors: TL
authors: Sharp
authors: Michael J
authors: MJ
authors: Welch
mesh_terms: D000818:Animals; D050197:Atherosclerosis / Q000000981:diagnostic imaging* / Q000378:metabolism*; D015415:Biomarkers / Q000378:metabolism; D018925:Chemokines / Q000493:pharmacokinetics*; D005263:Femoral Artery / Q000000981:diagnostic imaging / Q000293:injuries / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D057054:Molecular Imaging / Q000379:methods*; D009942:Organometallic Compounds / Q000493:pharmacokinetics*; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D019707:Receptors, Chemokine / Q000378:metabolism*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
chemical_list: C583338:(64)Cu-DOTA-vMIP-II; D015415:Biomarkers; D018925:Chemokines; D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; D019707:Receptors, Chemokine
keywords: atherosclerosis; chemokine receptors; molecular imaging; positron emission tomography; virus macrophage inflammatory protein
references: Arterioscler Thromb Vasc Biol. 2006 Aug;26(8):1858-63
references: 16763157
references: J Nucl Med. 2012 May;53(5):673-6
references: 22492729
references: Nat Rev Immunol. 2006 Jul;6(7):508-19
references: 16778830
references: Circulation. 2008 Nov 4;118(19):1953-60
references: 18936327
references: Br J Pharmacol. 2011 Apr;162(7):1453-69
references: 21133894
references: JACC Cardiovasc Imaging. 2011 Dec;4(12):1302-4
references: 22172787
references: Circ Res. 2012 Jul 6;111(2):231-44
references: 22773426
references: N Engl J Med. 2012 May 3;366(18):1734-6
references: 22551134
references: J Nucl Med. 2010 May 1;51 Suppl 1:33S-37S
references: 20395349
references: Blood. 2000 May 15;95(10):3032-43
references: 10807766
references: J Leukoc Biol. 2010 Jul;88(1):41-55
references: 20360402
references: J Nucl Med. 2011 Dec;52(12):1956-63
references: 22049461
references: J Control Release. 2009 Dec 3;140(2):100-7
references: 19666063
references: J Nucl Cardiol. 2009 Sep-Oct;16(5):753-62
references: 19662466
references: Arterioscler Thromb Vasc Biol. 2007 Oct;27(10):2079-93
references: 17600224
references: Circulation. 2012 Jan 3;125(1):e2-e220
references: 22179539
references: Cardiovasc Res. 2010 May 1;86(2):192-201
references: 20007309
references: Atherosclerosis. 2010 Aug;211(2):371-80
references: 20202637
references: J Am Coll Cardiol. 2009 Dec 1;54(23):2129-38
references: 19942084
references: N Engl J Med. 1999 Jan 14;340(2):115-26
references: 9887164
references: Can J Cardiol. 2012 Nov-Dec;28(6):662-6
references: 22902153
references: J Intern Med. 2011 Aug;270(2):99-109
references: 21518037
references: Mol Pharm. 2009 Nov-Dec;6(6):1891-902
references: 19852512
references: Trends Cardiovasc Med. 2011 Nov;21(8):211-6
references: 22902067
references: J Biol Chem. 2007 Jun 15;282(24):17794-805
references: 17403668
references: Nat Rev Cardiol. 2010 Jan;7(1):38-47
references: 19935740
references: Nature. 2002 Dec 19-26;420(6917):868-74
references: 12490960
references: J Nucl Med. 2010 Jan;51(1):85-91
references: 20008978
references: Nature. 2011 May 19;473(7347):317-25
references: 21593864
references: Nucl Med Biol. 1997 Jan;24(1):35-43
references: 9080473
references: J Nucl Med. 1991 Mar;32(3):475-80
references: 2005455
references: J Am Coll Cardiol. 1990 Jun;15(7):1667-87
references: 2188991
references: J Nucl Med. 2001 Nov;42(11):1643-52
references: 11696633
references: EMBO Mol Med. 2011 Dec;3(12):713-25
references: 22038924
references: Bioconjug Chem. 2012 Apr 18;23(4):671-82
references: 22242601
references: J Nucl Med. 2010 May 1;51 Suppl 1:51S-65S
references: 20395341
references: Nat Rev Drug Discov. 2010 Feb;9(2):141-53
references: 20118962
references: Science. 1997 Sep 12;277(5332):1656-9
references: 9287217
references: Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):77-83
references: 17962629